NON-REPLICATING RECOMBINANT SELF-COMPLEMENTARY (SC) ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9) VECTOR CONTAINING THE CDNA OF THE SURVIVAL OF MOTOR NEURON 2 (SMN2) GENE UNDER THE CONTROL OF THE HYBRID CYTOMEGALOVIRUS (CMV) ENHANCER/CHICKEN BETA-ACTIN PROMOTER (CBA)
Spinal Muscular Atrophy Type II
Novartis Gene Therapiesgene_therapyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Spinal Muscular Atrophy Type II cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Srk-015 Scholar Rock, Inc. | Phase 3 | BB |
OLESOXIME, E- Hoffmann-La Roche | Phase 2 | B |
Risdiplam Scholar Rock, Inc. | Phase 2 | CCC |
Nusinersen Scholar Rock, Inc. | Phase 2 | CCC |
Sodium Phenylbutyrate Westat | Phase 1/2 | CCC |
gc101 GeneCradle Inc | Phase 1/2 | CCC |
Gcb-001 Genecombio Ltd. | N/A | D |
oav101 Novartis Pharmaceuticals | Phase 3 | NR |
Same molecule, other indications
NON-REPLICATING RECOMBINANT SELF-COMPLEMENTARY (SC) ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9) VECTOR CONTAINING THE CDNA OF THE SURVIVAL OF MOTOR NEURON 2 (SMN2) GENE UNDER THE CONTROL OF THE HYBRID CYTOMEGALOVIRUS (CMV) ENHANCER/CHICKEN BETA-ACTIN PROMOTER (CBA) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →